Proton Pump Inhibitors in the COVID-19 Pandemic
The safety of proton pump inhibitors (PPIs) use in coronavirus infection (COVID-19) is not well understood. PPIs are potent suppressors of gastric secretion and become one of the ten most widely used drugs in the world. They are expected to influence virus susceptibility, severity, and outcomes in p...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
SINAPS LLC
2022-08-01
|
| Series: | Архивъ внутренней медицины |
| Subjects: | |
| Online Access: | https://www.medarhive.ru/jour/article/view/1477 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839572734049255424 |
|---|---|
| author | T. E. Kugler I. S. Malovichko V. B. Gnilitskaya A. L. Khristulenko N. F. Yarovaya |
| author_facet | T. E. Kugler I. S. Malovichko V. B. Gnilitskaya A. L. Khristulenko N. F. Yarovaya |
| author_sort | T. E. Kugler |
| collection | DOAJ |
| description | The safety of proton pump inhibitors (PPIs) use in coronavirus infection (COVID-19) is not well understood. PPIs are potent suppressors of gastric secretion and become one of the ten most widely used drugs in the world. They are expected to influence virus susceptibility, severity, and outcomes in patients diagnosed with COVID-19. This concern is based on their mechanism of action — suppression of gastric acidity, which is considered the first line of defense against infections. Taken together, the results of most studies and meta-analyses support that PPIs use has been associated with increased risk of COVID-19 and severe outcomes. However, taking into account all potential risk factors for disease severity seems impossible in the real world in the context of COVID-19, so conclusions about causal relationships between PPI use and COVID-19 should be treated with great caution. An additional interesting point about the use of PPIs in the pandemic is that it reduced absorption of certain vitamins. On the other hand, several studies have appeared in the literature regarding the protective therapeutic effects of PPIs. There is growing evidence of an immunomodulatory and antifibrotic role of PPIs that could be used in the treatment of COVID-19. In addition, their ability to alkalize the contents of endosomes and lysosomes serves as an obstacle to the penetration of the virus into host cells. This review analyzes the possible effects of PPIs in patients with COVID-19. |
| format | Article |
| id | doaj-art-6f706530eb6b4440b8c6c6838c44b3ba |
| institution | Matheson Library |
| issn | 2226-6704 2411-6564 |
| language | Russian |
| publishDate | 2022-08-01 |
| publisher | SINAPS LLC |
| record_format | Article |
| series | Архивъ внутренней медицины |
| spelling | doaj-art-6f706530eb6b4440b8c6c6838c44b3ba2025-08-04T14:09:48ZrusSINAPS LLCАрхивъ внутренней медицины2226-67042411-65642022-08-0112424525310.20514/2226-6704-2022-12-4-245-253899Proton Pump Inhibitors in the COVID-19 PandemicT. E. Kugler0I. S. Malovichko1V. B. Gnilitskaya2A. L. Khristulenko3N. F. Yarovaya4State Educational Organization of Higher Professional Education «M. Gorky Donetsk National Medical University»State Educational Organization of Higher Professional Education «M. Gorky Donetsk National Medical University»State Educational Organization of Higher Professional Education «M. Gorky Donetsk National Medical University»State Educational Organization of Higher Professional Education «M. Gorky Donetsk National Medical University»State Educational Organization of Higher Professional Education «M. Gorky Donetsk National Medical University»The safety of proton pump inhibitors (PPIs) use in coronavirus infection (COVID-19) is not well understood. PPIs are potent suppressors of gastric secretion and become one of the ten most widely used drugs in the world. They are expected to influence virus susceptibility, severity, and outcomes in patients diagnosed with COVID-19. This concern is based on their mechanism of action — suppression of gastric acidity, which is considered the first line of defense against infections. Taken together, the results of most studies and meta-analyses support that PPIs use has been associated with increased risk of COVID-19 and severe outcomes. However, taking into account all potential risk factors for disease severity seems impossible in the real world in the context of COVID-19, so conclusions about causal relationships between PPI use and COVID-19 should be treated with great caution. An additional interesting point about the use of PPIs in the pandemic is that it reduced absorption of certain vitamins. On the other hand, several studies have appeared in the literature regarding the protective therapeutic effects of PPIs. There is growing evidence of an immunomodulatory and antifibrotic role of PPIs that could be used in the treatment of COVID-19. In addition, their ability to alkalize the contents of endosomes and lysosomes serves as an obstacle to the penetration of the virus into host cells. This review analyzes the possible effects of PPIs in patients with COVID-19.https://www.medarhive.ru/jour/article/view/1477proton pump inhibitorscovid-19sars-cov-2pneumoniamortalitysevere outcomesrisk factorstreatmentvitamins |
| spellingShingle | T. E. Kugler I. S. Malovichko V. B. Gnilitskaya A. L. Khristulenko N. F. Yarovaya Proton Pump Inhibitors in the COVID-19 Pandemic Архивъ внутренней медицины proton pump inhibitors covid-19 sars-cov-2 pneumonia mortality severe outcomes risk factors treatment vitamins |
| title | Proton Pump Inhibitors in the COVID-19 Pandemic |
| title_full | Proton Pump Inhibitors in the COVID-19 Pandemic |
| title_fullStr | Proton Pump Inhibitors in the COVID-19 Pandemic |
| title_full_unstemmed | Proton Pump Inhibitors in the COVID-19 Pandemic |
| title_short | Proton Pump Inhibitors in the COVID-19 Pandemic |
| title_sort | proton pump inhibitors in the covid 19 pandemic |
| topic | proton pump inhibitors covid-19 sars-cov-2 pneumonia mortality severe outcomes risk factors treatment vitamins |
| url | https://www.medarhive.ru/jour/article/view/1477 |
| work_keys_str_mv | AT tekugler protonpumpinhibitorsinthecovid19pandemic AT ismalovichko protonpumpinhibitorsinthecovid19pandemic AT vbgnilitskaya protonpumpinhibitorsinthecovid19pandemic AT alkhristulenko protonpumpinhibitorsinthecovid19pandemic AT nfyarovaya protonpumpinhibitorsinthecovid19pandemic |